These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

584 related items for PubMed ID: 33857539

  • 1. Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
    Scudeller L, Righi E, Chiamenti M, Bragantini D, Menchinelli G, Cattaneo P, Giske CG, Lodise T, Sanguinetti M, Piddock LJV, Franceschi F, Ellis S, Carrara E, Savoldi A, Tacconelli E.
    Int J Antimicrob Agents; 2021 May; 57(5):106344. PubMed ID: 33857539
    [Abstract] [Full Text] [Related]

  • 2. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
    Ardebili A, Izanloo A, Rastegar M.
    Expert Rev Anti Infect Ther; 2023 Apr; 21(4):387-429. PubMed ID: 36820511
    [Abstract] [Full Text] [Related]

  • 3. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA.
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa.
    Mikhail S, Singh NB, Kebriaei R, Rice SA, Stamper KC, Castanheira M, Rybak MJ.
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182535
    [Abstract] [Full Text] [Related]

  • 5. In vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam alone or in combination with polymyxin B against carbapenem resistant Acinetobacter baumannii.
    Liang R, Wang D, Hu M, Gu Y, Wang M, Hu D, Zhu M, Wang M.
    J Antibiot (Tokyo); 2023 Sep; 76(9):540-547. PubMed ID: 37217796
    [Abstract] [Full Text] [Related]

  • 6. In Vitro Activity of Ceftazidime-Avibactam Alone and in Combination with Amikacin Against Colistin-Resistant Gram-Negative Pathogens.
    Chen T, Xu W, Yu K, Zeng W, Xu C, Cao J, Zhou T.
    Microb Drug Resist; 2021 Mar; 27(3):401-409. PubMed ID: 32721272
    [No Abstract] [Full Text] [Related]

  • 7. Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa.
    Avery LM, Sutherland CA, Nicolau DP.
    J Med Microbiol; 2019 Jun; 68(6):893-897. PubMed ID: 31050629
    [Abstract] [Full Text] [Related]

  • 8. A Systematic Review of the Pharmacokinetics and Pharmacodynamics of Novel Beta-Lactams and Beta-Lactam with Beta-Lactamase Inhibitor Combinations for the Treatment of Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria.
    Rando E, Novy E, Sangiorgi F, De Pascale G, Fantoni M, Murri R, Roberts JA, Cotta MO.
    Int J Antimicrob Agents; 2024 Sep; 64(3):107266. PubMed ID: 38971203
    [Abstract] [Full Text] [Related]

  • 9. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA.
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [Abstract] [Full Text] [Related]

  • 10. Predicting early appropriate therapy for patients infected by carbapenem-resistant Gram-negative pathogens in intensive care units in Italy.
    Bassetti M, Monti G, Henriksen AS, Longshaw C.
    Antimicrob Resist Infect Control; 2024 Aug 26; 13(1):91. PubMed ID: 39183351
    [Abstract] [Full Text] [Related]

  • 11. Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases.
    Meschiari M, Asquier-Khati A, Tiseo G, Luque-Paz D, Murri R, Boutoille D, Falcone M, Mussini C, Tattevin P, Italian Society of Infectious and Tropical Diseases (SIMIT), and the French Society of Infectious Diseases (SPILF).
    Int J Antimicrob Agents; 2024 Jul 26; 64(1):107186. PubMed ID: 38688353
    [Abstract] [Full Text] [Related]

  • 12. Synergistic Activity of Cefiderocol in Combination with Avibactam, Sulbactam or Tazobactam against Carbapenem-Resistant Gram-Negative Bacteria.
    Lewis RE, Palombo M, Diani E, Secci B, Gibellini D, Gaibani P.
    Cells; 2024 Aug 06; 13(16):. PubMed ID: 39195205
    [No Abstract] [Full Text] [Related]

  • 13. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems.
    Zusman O, Avni T, Leibovici L, Adler A, Friberg L, Stergiopoulou T, Carmeli Y, Paul M.
    Antimicrob Agents Chemother; 2013 Oct 06; 57(10):5104-11. PubMed ID: 23917322
    [Abstract] [Full Text] [Related]

  • 14. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
    Hsueh SC, Lee YJ, Huang YT, Liao CH, Tsuji M, Hsueh PR.
    J Antimicrob Chemother; 2019 Feb 01; 74(2):380-386. PubMed ID: 30357343
    [Abstract] [Full Text] [Related]

  • 15. Susceptibility of Multidrug-Resistant Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa from Germany to Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Imipenem-Relebactam.
    Kresken M, Wohlfarth E, Wichelhaus TA, Gatermann SG, Pfennigwerth N, Eisfeld J, Seifert H, German BL/BLI Study Group.
    Microb Drug Resist; 2023 Apr 01; 29(4):138-144. PubMed ID: 36622756
    [Abstract] [Full Text] [Related]

  • 16. The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia.
    Clerici D, Oltolini C, Greco R, Ripa M, Giglio F, Mastaglio S, Lorentino F, Pavesi F, Farina F, Liberatore C, Castiglion B, Tassan Din C, Bernardi M, Corti C, Peccatori J, Scarpellini P, Ciceri F, Castagna A.
    Int J Antimicrob Agents; 2021 Jun 01; 57(6):106335. PubMed ID: 33838223
    [Abstract] [Full Text] [Related]

  • 17. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
    Falagas ME, Skalidis T, Vardakas KZ, Legakis NJ, Hellenic Cefiderocol Study Group.
    J Antimicrob Chemother; 2017 Jun 01; 72(6):1704-1708. PubMed ID: 28369471
    [Abstract] [Full Text] [Related]

  • 18. In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli.
    Schmidt-Malan SM, Mishra AJ, Mushtaq A, Brinkman CL, Patel R.
    Antimicrob Agents Chemother; 2018 Aug 01; 62(8):. PubMed ID: 29760145
    [Abstract] [Full Text] [Related]

  • 19. In vitro activity of imipenem-relebactam alone and in combination with fosfomycin against carbapenem-resistant gram-negative pathogens.
    Xu C, Chen T, Zhang S, Zhou C, Liao W, Fang R, Chen L, Zhou T.
    Diagn Microbiol Infect Dis; 2022 Jul 01; 103(3):115712. PubMed ID: 35613493
    [Abstract] [Full Text] [Related]

  • 20. Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018).
    Sader HS, Flamm RK, Carvalhaes CG, Castanheira M.
    Diagn Microbiol Infect Dis; 2020 Mar 01; 96(3):114833. PubMed ID: 31924426
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.